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Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is
becoming increasingly common in patients with type 2 diabetes. However,
approximately 40% of patients fail to reach their glycemic targets with the initially
prescribed regimen and require intensification of insulin therapy, which increases
the risks of weight gain and hypoglycemia. Many of these patients eventually
reach a state in which further increases in the insulin dosage fail to improve
glycemic control while increasing the risks of weight gain and hypoglycemia. The
recently completed OpT2mise clinical trial showed that continuous subcutaneous
insulin infusion (CSII) is more effective in reducing glycated hemoglobin (HbA1c)
than intensification of multiple daily injection (MDI) insulin therapy in patients
with type 2 diabetes who do not respond to intensive insulin therapy. CSII therapy
may also be useful in patients who do not reach glycemic targets despite multi-
drug therapy with basal-bolus insulin and other agents, including glucagon-like
peptide (GLP)-1 receptor agonists; current guidelines offer no recommendations
for the treatment of such patients. Importantly, insulin and GLP-1 receptor ago-
nists have complementary effects on glycemia and, hence, can be used either
sequentially or in combination in the initial management of diabetes. Patients
who have not previously failed GLP-1 receptor agonist therapy may show reduc-
tion in weight and insulin dose, in addition to moderate improvement in HbA1c,
when GLP-1 receptor agonist therapy is added to MDI regimens. In subjects with
long-standing type 2 diabetes who do not respond to intensive insulin therapies,
switching fromMDI to CSII and/or the addition of GLP-1 receptor agonists toMDI have
thepotential to improve glycemic controlwithout increasing the risk of adverseevents.
Type 2 diabetes is a progressive disease caused by increasingly severe b-cell dys-
function (1). Preventive strategies have been unsuccessful in curbing the increase
in the prevalence of the disease (2), and although more than 10 classes of hypogly-
cemic medications have been developed to treat type 2 diabetes, none have been
shown to ensure robust, sustained glycemic control over the course of the disease
(3). As a result, increasing numbers of patients are being treated with insulin alone
or, more commonly, as an adjunct to oral or injectable hypoglycemic therapy.
However,;40% of patients treated with this approach fail to achieve their glycated
hemoglobin (HbA1c) targets with basal insulin therapy and require additional treat-
ment with boluses of short-acting insulin preparations (4). Unfortunately, in some
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patients, these intensified insulin regi-
mens also eventually prove to be inef-
fective in ensuring glycemic control, and
they often increase the risk of adverse
events such as weight gain and hypogly-
cemia (5). The mechanisms underlying
this loss of response have not been ex-
tensively studied.
When a multiple daily injection (MDI)
regimen fails to achieve the target
HbA1c, there are some options available
to patients, including adding glucagon-
like peptide 1 (GLP-1) receptor agonists
(GLP-1 RAs), adding sodium–glucose
cotransporter 2 inhibitors, or undergo-
ing bariatric surgery. The recently com-
pleted randomized, open-label trial
OpT2mise (6) has provided evidence
that continuous subcutaneous insulin
infusion (CSII) is more effective in reduc-
ing HbA1c levels than intensification of
MDI insulin therapy in patients with
type 2 diabetes in whom adequate gly-
cemic control cannot be achieved with
intensive basal-bolus insulin regimens.
This article will focus on two of these
options: adding GLP-1 RA to MDI and
switching from MDI to CSII.
We performed a literature review to
identify published studies in English of
patients with type 2 diabetes treated
with MDI and failing to reach glycemic
goals using the followingMeSH (Medical
Subject Headings) terms search string:
(“diabetes mellitus, type 2”[MeSH
Terms] OR “type 2 diabetes mellitus”[All
Fields] OR “diabetes mellitus type 2”[All
Fields]) AND (mdi[All Fields] OR (multi-
ple[All Fields] AND daily[All Fields] AND
(“injections”[MeSH Terms] OR “injec-
tions”[All Fields]))) AND (“2006/02/
09”[PDat]: “2015/02/06”[PDat]). A total
of 112 hits were identified by the
PubMed search; 91 references were
excluded. Of the remaining 18 articles,
4 were on the addition of pioglitazone,
acarbose empagliflozin, and sitagliptin
(1 article per drug); 2 on the addition of
GLP-1RAs; and15onCSII in type2diabetes.
WHAT EVIDENCE DO WE HAVE
THAT CSII MIGHT OFFER BENEFITS
FOR PATIENTS WITH TYPE 2
DIABETES THAT IS POORLY
CONTROLLED WITH MDI INSULIN
THERAPY?
Four randomized controlled studies
have compared the efficacies of pump
treatment and MDI in lowering HbA1c
in patients with type 2 diabetes (5). In
the two trials with parallel-group designs,
the benefits of pump therapy were simi-
lar to those of intensified MDI treatment
(7,8), whereas the two randomized cross-
over studies (9,10) found that pump
treatment was superior to MDI.
A larger randomized controlled trial,
OpT2mise (6), was designed to resolve
this discrepancy. In this study,.300 pa-
tients in whom adequate glycemic con-
trol was not achieved despite optimized
MDI therapy were randomized to ongo-
ing treatmentwith either optimizedMDI
insulin therapy or CSII. After 6 months of
treatment, the mean (SD) HbA1c level had
decreasedby 1.1 (1.2)% (12 [13]mmol/mol)
in the CSII group compared with only 0.4
(1.1)% (4 [12] mmol/mol) in the MDI
groupda highly significant difference of
–0.7% (95% CI –0.9 to –0.4) (–8 mmol/mol
[95% CI –10 to –4]), P , 0.0001). The
improved glycemic control achieved
with pump therapy was independent of
age, sex, cognitive state, fasting C-peptide
levels, and anti-GAD antibody status. In
addition, insulin doses in the pump therapy
group were 20% lower than those of the
groupmanagedwithMDI,andnosignificant
between-group differences were observed
in the rates of severe adverse events or hy-
poglycemia, which were low in both cases.
WHAT KIND OF PATIENTS WITH
TYPE 2 DIABETES MIGHT BE
EXPECTED TO BENEFIT FROM A
SWITCH FROM MDI TO PUMP
THERAPY?
Type 2 diabetes is a heterogeneous
disease at both the phenotype and ge-
notype levels. Interactions between
genetic, environmental, and behavioral
factorsdnot to mention those related
to the microbiota (11)dresult in sub-
stantial phenotypic variability, and, as
noted above, this variability is reflected
in the heterogeneous responses to dif-
ferent drugs. This is the reason so much
emphasis is currently being placed on
the importance of “precision medi-
cine,” whereby therapy is tailored to
the specific needs and characteristics
of the individual patient.
One of the major strengths of the
OpT2mise trial, compared with previous
comparisons ofMDI with pump therapy,
is that it focused selectively on a very
well-defined subpopulation of patients
with type 2 diabetes whose needs
are a major challenge for diabetologists
the world over: patients who were
insulin resistant and had HbA1c levels
that remained .8% (64 mmol/mol) af-
ter $3 months of aggressive multidrug
treatment. This treatment included at
least three daily injections of insulin
analogs (rapid- and long acting) and an
additional 2-month period of dose titra-
tion to a minimum total dose of 0.7
units/kg/day (12). The characteristics
of these patients, which are shown in
Table 1, are similar to those of patients
with type 2 diabetes who have benefited
from CSII in French cohort studies
(13,14): late-middle-aged individuals
with long-standing diabetes, level I obe-
sity, and a mean HbA1c level that re-
mains above the target range, despite
aggressive treatment.
Patients of this type are by no means
rare in routine clinical practice. In fact,
the Swedish National Diabetes Register
(the world’s most comprehensive na-
tional diabetes registry) recently report-
ed that HbA1c levels.8.8% (73mmol/mol)
are present in almost 1 in 10 patients
with type 2 diabetes and.1 in 5 of those
being treated in specialist clinics. Fur-
thermore, most of these individuals are
already being treated with insulin, alone
or with other hypoglycemic medica-
tions (15). Of note, CSII as replacement
of MDI for intensive insulin therapy has
safety concerns with respect to cardio-
vascular and all-cause mortality similar
to those of MDI, as discussed in recent
publications (16,17).
WHAT ARE THE PATIENT
EDUCATION NEEDS NECESSARY
FOR CSII TREATMENT IN TYPE 2
DIABETES?
Device handling for patients with type 2
diabetes with age- and diabetes-related
cognitive and dexterity decline might be
complicated with current pump devices
(5). In the OpT2mise study, patients as-
signed to pump treatment underwent
up to 3 weeks’ training with additional
visits (6). Simplifying future pumps and
related procedures with use of prefilled
cartridges can potentially be advanta-
geous. Experience from several cohorts
and data from the OpT2mise study dem-
onstrate that need for complex bolus dos-
ing, meal carbohydrate estimates, and
multiple basal rates are not necessary in
most patients with type 2 diabetes (as op-
posed to the case in patients with type 1
diabetes) and that the majority of patients
attain autonomy in the use of CSII (18).
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Simple pump programming achieved
significant glycemic control, not unlike
more complex regimens (6), and was
deemed safe and easy for use by physi-
cians in secondary and primary clinics
(19). Thus, a simple approach for pump
use in type 2 diabetes management can
decrease regimen complexity and en-
courage patients and caretakers to use
CSII. While there is a need for an in-
crease in patient interaction at the initi-
ation of CSII therapy, the 12-month
outcome of the OpT2mise study exten-
sion indicates that it has a lasting effect
without further need of additional CSII-
related visits (20).
WHAT PLACE DOES INSULIN
PUMP THERAPY HAVE IN THE
TREATMENT OF TYPE 2 DIABETES?
Transient use of intensive insulin ther-
apy in the initial phases of type 2 dia-
betes is intended to preserve b-cell
function, and it has been reported to
significantly improve remission rates
(21–23). However, most national and in-
ternational guidelines recommend MDI
therapy as a last resort to be imple-
mented after all previous therapies (in-
cluding oral or injectable hypoglycemic
agents or combinations of these) have
failed to achieve therapeutic goals
(24,25). These recommendations are
based on extensive clinical experience
and study data, which have demonstrated
the efficacy of basal-bolus insulin therapy
in improving glycemic control in patients
with long-standing type 2 diabetes.
As noted earlier, however, adding
MDI often does not suffice. In the Treat-
ing To Target in Type 2 Diabetes (4-T)
trial, ;30–50% of patients will not
achieve their HbA1c target with this ap-
proach, irrespective of the specific insu-
lin regimen used (4). Similar findings have
been observed in studies comparing MDI
insulin therapy with premixed insulin for-
mulations, in which;35–40% of patients
did not reach glycemic control targets
with MDI regimens (26,27).
These data suggest that the needs of
a significant proportion of patients are
not beingmet withMDI regimens. Alter-
natives recommended by current guide-
lines include bariatric surgery, which is
indicated only in selected cases, and the
addition of other oral drugs, such as
GLP-1 RAs (discussed in greater detail
below): CSII is not even considered in
international guidelines (24,25,28) or
in national guidelines, notably, the cur-
rent National Institute for Health and
Care Excellence guidelines from the
U.K. (29). It is to be hoped that this omis-
sion will be reconsidered in the near
future, in light of the results of the
OpT2mise trial. Pump therapy has also
been shown to be effective in pa-
tients with type 2 diabetes during acute
stages of disease and during pregnancy
(30).
Cost is an important consideration for
usage of a treatment by a health care
system, but an in-depth discussion on
cost-effectivenesss is beyond the scope
of this article and has significant re-
gional differences. Although initial costs
associated with CSII are high, improve-
ments in HbA1c with a decrease in over-
all insulin requirements observed with
CSII versus MDI may offer important re-
ductions in diabetes-related complica-
tions and associated costs, as recently
assessed in the U.K. in the setting of
uncontrolled type 2 diabetes (31).
WHAT EVIDENCE DO WE HAVE
THAT THE ADDITION OF GLP-1
RAS MIGHT OFFER BENEFITS FOR
PATIENTS WITH TYPE 2 DIABETES
THAT IS POORLY CONTROLLED
WITH BASAL INSULIN THERAPY?
Insulin therapy is a very effective means
of treating hyperglycemia; however, the
great reluctance by patients and doctors
to initiate and intensify insulin therapy
means that HbA1c goals are often unmet
(32). GLP-1 RAs have also been shown to
be effective in treating hyperglycemia
and normalizing plasma glucose concen-
trations in patients with type 2 diabetes
(33). The glucose-lowering effect of
GLP-1 RA therapy is glucose dependent.
Therefore, and in contrast to prandial
insulin, GLP-1 RA therapy added to basal
insulin is associated with a lower risk of
Table 1—Baseline characteristics of patients with type 2 diabetes enrolled in the
OpT2mise study (6)
CSII pump therapy
(n = 168)
MDI therapy
(n = 163)
Age (years) 55.5 (9.7) 56.4 (9.5)
Sex (male/female), n (%) 94 (56.0)/74 (44.0) 86 (52.8)/77 (47.2)
Ethnic origin, n (%)
Caucasian 162 (96.4) 156 (95.7)
Black African 6 (3.6) 7 (4.3)
Duration of diabetes (years) 14.9 (8.0) 15.3 (8.0)
HbA1c, % [mmol/mol] 9.0 (0.75) [75 (8.2)] 9.0 (0.76) [75 (8.3)]
Weight (kg) 97.3 (22.6) 94.9 (22.0)
BMI (kg/m2) 33.5 (7.5) 33.2 (7.0)
Systolic blood pressure (mmHg) 132.3 (15.2) 131.9 (14.8)
Diastolic blood pressure (mmHg) 75.6 (9.4) 76.0 (10.6)
Total cholesterol (mmol/L) 4.5 (1.4) 4.4 (1.0)
HDL (mmol/L) 1.2 (0.4) 1.4 (0.4)
LDL (mmol/L) 2.2 (0.8) 2.2 (0.8)
Triglycerides (mmol/L) 2.3 (2.4) 1.9 (1.6)
Smokers, n (%) 24 (14.3) 25 (15.3)
Metformin use, n (%) 120 (71.4) 112 (68.7)
Metformin dose (mg/day) 1,810 (679.8) 1,788 (636.1)
Total daily insulin dose (units/kg) 1.1 (0.4) 1.1 (0.4)
Total daily insulin dose (units) 112.3 (53.9) 106.2 (49.2)
Total long-acting insulin dose (units/day) 57.4 (30.3) 52.4 (27.7)
Total rapid-acting insulin dose (units/day) 55.6 (31.7) 53.8 (30.8)
Diabetes complications and comorbidities, n (%)
Dyslipidemia 26 (15.5) 16 (9.8)
Cardiac-related diseases 142 (84.5) 137 (84.0)
Peripheral vascular disease 12 (7.1) 7 (4.3)
Retinopathy 6 (3.6) 3 (1.8)
Diabetic nephropathy 22 (13.1) 12 (7.4)
Peripheral neuropathy 0 (0) 0 (0)
Data are presented as mean (SD) unless otherwise indicated.
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hypoglycemia, without compromising
HbA1c reduction (34,35). The lower
rate of observed hypoglycemia could
also be attributed to the lower insulin
dose required when adding GLP-1 RA
to patients on insulin regimens (36). Re-
duction of hypoglycemia is also related
to the prevailing event rate of hypogly-
cemia. Patients uncontrolled on MDI
who exhibit severe insulin resistance
and/or a high level of obesity show low
rates of hypoglycemia (6,37), thus di-
minishing the advantage of GLP-1 RAs
in reducing hypoglycemia events while
retaining their beneficial weight reduc-
tion effect (37). Here again, however,
even with the highest tolerated doses
of GLP-1 RAs, only approximately half
of patients reach HbA1c levels ,7% (53
mmol/mol) (38).
A large body of evidence currently
demonstrates that combining these
two modalities is an advantageous ap-
proach. Basal insulin analogs provide di-
urnal and especially nocturnal coverage
during fasting periods, reducing hepatic
glucose production and resulting in im-
provements in nocturnal and fasting
plasma glucose levels (39). GLP-1 RAs
stimulate insulin secretion and suppress
glucagon secretion, both in a glucose-
dependent manner, with marked reduc-
tions in postprandial glucose levels (40),
thereby providing a complementary
mechanism of action to basal insulin.
In addition, weight loss often experi-
enced with GLP-1 RAs can counteract
theweight gain causedby insulin therapy.
Randomized, placebo-controlled trials
evaluating use of GLP-1 RAs in conjunc-
tionwith basal insulin have demonstrated
meaningful reductions in HbA1c, weight
loss, and low risk of hypoglycemia (41–
45). Consistently, recent studies with
fixed-dose mixtures of the various GLP-1
RAs classesdshort-acting lixisenatide
and insulin glargine (LixiLan-l phase III
study)dand the completed series of
studies with daily liraglutide and insulin
degludec (Dual Action of Liraglutide and
Insulin Degludec in Type 2 Diabetes
[DUAL] studies) demonstrated the preser-
vation of the dual effect of each compo-
nent in HbA1c reduction with decreasing
hypoglycemia andweight gain in compar-
ison with strategies of uptitration of basal
insulin or MDI regimens. Furthermore, pa-
tients on the fixed-combination GLP-1
and basal insulin had lesser gastrointesti-
nal side effects than seen when each
component is titrated separately. A re-
view of the studies with combined insulin
degludec and liraglutide (46) demon-
strated the increased odds for achieving
HbA1c ,7.0% without hypoglycemia and
no weight gain versus uptitrated insulin
glargine. The improved outcome was as-
sociatedwitha reduction of regimen com-
plexity related to fewer injections per day.
An alternative approach for decreasing
treatment complexity has been studied
with once-weekly GLP-1 RA dulaglutide
in the AWARD-4 trial, which studied
combination therapy with insulin/GLP-1
RA in combination with insulin lispro
(47). Here, the comparison was between
once-weekly dulaglutide and daily glar-
gine, both, in addition to mealtime lispro
and metformin. The adjusted mean HbA1c
difference versus glargine was statistically
significant but small (–0.25% [95%CI –0.42
to –0.07], –2.73 mmol/mol [95% CI –4.59
to –0.77]; P = 0.005), with no significant
differences in hypoglycemia incidence
and with a clinically relevant between-
group weight difference of 3.2 kg. The
once-weekly dose of dulaglutide was as-
sociated with improvement in several pa-
tient outcome measures (48).
Other randomized controlled trials
compared the addition of GLP-1 RA ver-
sus bolus insulin in patients who had not
reached HbA1c goals on oral medications
and basal insulin. These studies demon-
strated that adding GLP-1 RA was compa-
rable with adding prandial insulin three
times a day to basal insulin therapy with
regard to improving glucose control, with
the added value of weight loss and less
hypoglycemia and the advantage of hav-
ing fewer injections, although with a
higher rate of gastrointestinal side effects
(49,50). From these studies, one could
extrapolate that adding GLP-1 RAs to
more complex MDI regimens would also
be beneficial.
A substantial body of evidence is there-
fore in favor of combining basal insulin
and GLP-1 RAs early in the course of ther-
apy, with evidence for a lower risk of hy-
poglycemia and weight loss without
compromising HbA1c reduction compared
with the addition of mealtime bolus insu-
lin. We would also suggest that MDI re-
fractoriness should be considered only
after therapeutic trials with GLP-1 RAs
have been attempted when appropriate.
ADDING GLP-1 RAS TO MDI
INSULIN REGIMEN
Two randomized prospective controlled
trials that investigated the effect of GLP-1
RA therapy added to intensive (basal-
bolus) insulin therapy have very recently
been published in the English literature
(51,52). The trials’ approach and objec-
tives differed from each other and from
those of the OpT2mise trial, thus pre-
cluding direct comparison between
these trials (Table 2). Lane et al. (51)
evaluated the effect of the addition of
liraglutide to high-dose intensive insulin
therapy compared with standard insulin
uptitration in morbid obese insulin-
resistant patients with type 2 diabetes
requiring high-dose insulin therapy. The
objective was to decrease weight and re-
duce insulin dose. Thirty-seven subjects
with type 2 diabetes requiring .100
units of insulin daily administered either
by CSII or by MDI with or without met-
formin were randomized to receive ei-
ther liraglutide titrated to 1.8 mg plus
insulin or intensive insulin only (control
Table 2—Comparison of prospective randomized studies on add-on therapy for
patients with type 2 diabetes on MDI
Lane et al.
(51)
MDI Liraglutide trial
(52)
FLAT-SUGAR
(53)
OpT2mise
(6)
n 37 124 102 495
Age (years) 59.7 63.7 62 56.4
Diabetes duration
(years) 17.1 17.3 15 15.2
HbA1c (%) 7.8 9.0 7.9 9.4
BMI (kg/m2) 41 33.7 33.9 33.6
TDD 187 105.3 104.9
DHbA1c (%) 20.2 21.1 20.7
DWeight (kg) 25.6 23.8 0.4
DInsulin (units) 246 215.8 225
Data are means. TDD, total daily dose.
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subjects). At 6 months, subjects receiv-
ing liraglutide plus insulin experienced
statistically significant reduction of 0.26%
in HbA1c and reductions in weight, insulin
dose, and glycemic variability as mea-
sured by a continuous glucose monitor
compared with the control group receiv-
ing only insulin. In the recent published
MDI Liraglutide trial (52), targeting pa-
tients with HbA1c uncontrolled on MDI
without concomitant hypoglycemic med-
ication (either oral or injectable) resulted
in a significant reduction of 1.13% (95%
CI21.45 to20.81; P , 0.001) in HbA1c,
with reductions in weight (mean 3.8 kg)
and insulin dose (mean 15.8 units). As
the patients in this study were not on
concomitant medications for glycemic
control for .3 months, they are not
characteristic of the common practice
where MDI therapy is usually added on
and is combined with metformin and/or
other classes of medications, including
GLP-1 RAs. This study does provide ev-
idence that GLP-1 RA therapy is effec-
tive in addition to MDI treatment in
patients with long-standing diabetes
and high HbA1c.
Further insights into this issue may
emerge from FLuctuATion reduction
with inSUlin and Glp-1 Added togetheR
(FLAT-SUGAR) (53), which investigated
the effect of replacing preprandial
short-acting insulin analogs with pre-
prandial exenatide in patients with
poorly controlled glycemia despite in-
tensive basal-bolus insulin regimens,
who were at high risk for cardiovascular
events (mean age 62 years, mean dura-
tion of diabetes 15 years, mean BMI
33.9 kg/m2, and mean baseline HbA1c
7.9%). FLAT-SUGAR is not a treat-to-target
study, precluding comparison of relative
effectiveness efficacy of HbA1c lowering
with the OpT2mise trial. Preliminary
findings presented at the recent Amer-
ican Diabetes Association 2015 Scientific
Sessions indicate that basal insulin plus
mealtime administration of exenatide
can be as effective in reducing HbA1c
levels as basal-bolus insulin therapy
(7.1 vs. 7.2% after 26 weeks of therapy),
and it is also associated with signifi-
cantly greater weight loss (4.7 kg loss
vs. 0.8 kg gain in the basal-bolus insulin
group; P , 0.001). It is interesting to
note that in several respects the FLAT-
SUGAR population resembles that of
the OpT2mise trial, where CSII proved to
be significantlymore effective in reducing
HbA1c levels than intensive basal-bolus in-
sulin therapy (even when the latter was
combined with GLP-1 RAs or other
agents) and no more likely than the
latter to cause excessive weight gain.
It would therefore be interesting to
see how the two strategies could be
combined.
A prospective, observational study by
van Velsen et al. (54) investigated 125
obese patients treated with insulin in a
clinical practice setting who were
started on a GLP-1 RA (liraglutide or ex-
enatide). Seventy-four patients (59%)
were taking four injections of insulin
per day, and three patients (2%) were
on an insulin pump. The study showed
that HbA1c and weight decreased signif-
icantly at all time points (P # 0.001 com-
pared with baseline; HbA1c25.5 mmol/mol
[20.5%] and weight 214.3 kg after 12
months), with the largest decrease in
the first 3 months. After 6 and 12
months, the total daily insulin dose de-
creased significantly (P , 0.001; 275.4
IU after 12 months). Moreover, 34% of
the patients were able to stop using in-
sulin therapy after 12 months (excluding
19% of patients who failed to improve or
stopped liraglutide medication owing to
adverse effects). In short, they found
that adding a GLP-1 RA to treatment of
obese patients with type 2 diabetes al-
ready on insulin therapy led to a signifi-
cant reduction of HbA1c levels, body
weight, and insulin dose.
Other retrospective studies reached
similar conclusions. One study (55) eval-
uated the effect of exenatide 5 mg twice
daily on clinical parameters in 52 obese
patients with type 2 diabetes whose hy-
perglycemia was not adequately con-
trolled despite treatment with oral
hypoglycemic agents and insulin. Mean
follow-up period was 26 weeks. The 38
patients who took exenatide regularly
were compared with the 14 patients
who discontinued exenatide because
of insurance, personal, or economic rea-
sons (control group). Measurements at
baseline and at follow-up showed that
mean body weight decreased by 6.466
0.8 kg (P , 0.001) in the exenatide
group, while it increased by 2.4 6 0.6 kg
in the control group (P , 001). In the
exenatide group, mean HbA1c decreased
by 0.6 6 0.21% (P = 0.007), and the in-
sulin dosage requirement decreased for
rapid-acting and mixed insulins (P ,
0.02). In the exenatide group, there
was a decrease in total cholesterol by
8.5 6 3.3% (P = 0.03), triglycerides by
266 7.6% (P = 0.01), systolic blood pres-
sure by 9.2 6 3.3 mmHg (P = 0.02), and
hs-CRP by 34 6 14.3% (P = 0.05). These
indices did not change in the control
group.
Other similar retrospective studies
also concluded that the addition of a
GLP-1 RA effectively treats obese pa-
tients with type 2 diabetes on insulin,
leading to weight loss and reduction in
levels of HbA1c, total and prandial insu-
lin doses, systolic blood pressure, tri-
glycerides, and hs-CRP, along with a
low risk of hypoglycemia (56). These im-
provements were also evidenced in a
study where liraglutide was added to
an MDI regimen in very insulin-resistant
patients taking U-500 insulin with a
mean daily dose of 192 units (37). After
12 weeks, liraglutide reduced HbA1c by
1.4% (mean baseline HbA1c 8.5%), while
insulin dose was reduced by 28%. There
were no reports of hypoglycemia, and
body weight was reduced by 5 kg (base-
line body weight 136 kg). Furthermore,
the addition of GLP-1 RA to complicated
MDI treatment seems to be associated
with high treatment satisfaction (57),
though it still remains unclear how sus-
tainable the effect is during long-term
treatment (58).
ELEMENTS THAT MAY FAVOR THE
CHOICE OF ONE OR THE OTHER
OPTION
As no studies directly comparing GLP-1
RA versus insulin pump are available,
current knowledge and experience
may suggest the following rationale in
the decision-making process.
No Previous Exposure to GLP-1 RAs
Patients failing MDI, not previously
treated by GLP-1 RAs, can benefit
from a therapeutic trial of these drugs
according to Lind et al. (52).
High HbA1c Levels
At HbA1c .8.5%, the advantage of CSII
is more pronounced, and therefore
switching patients for whom MDI failed
to CSII is warranted. Addition or contin-
uation of GLP-1 RA can then be consid-
ered (6).
High BMI
Obese patients for whomMDI failed can
benefit from the weight reduction in-
duced by GLP-1 RAs (37). Recent studies
have demonstrated that increasing
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liraglutide dose beyond 1.8mg, up to 3mg
daily, can cause additional weight loss
without further reductions in HbA1c (59).
High Glycemic Excursions
Patients characterized by high overall
glucose levels and relatively low SD
and MAGE on a 24-h continuous glyce-
mic profile, as in the OpT2mise trial (60),
can successfully be treated by insulin
pumps, while patients with higher post-
prandial glycemic excursions, as measured
by SD,MAGE, or other indices,may benefit
more fromGLP-1 RA therapy, as suggested
by Monnier and Colette (61).
CONCLUDING REMARKS
A significant proportion of patients with
type 2 diabetes, moderate obesity, and
long-standing disease do not reach ade-
quate glycemic control despite intensive
insulin regimens. At this stage, the only
therapeutic alternative offered by cur-
rent guidelines is bariatric surgery,
which is still limited to selected patients.
The OpT2mise trial demonstrated that
switching to insulin pump therapy can
enhance insulin action in this subset of
patients, without significantly increas-
ing adverse events such as hypoglyce-
mia and weight gain. As suggested by
the recent prospective controlled trials,
adding a GLP-1 RA cannot replace inten-
sive insulin therapy, although it still may
be helpful in controlling weight gain and
glycemic excursions.
In conclusion, when patients on MDI
regimens have still not reached their
target glycemic control, while on GLP-1
RA therapy, switching to CSII is an effec-
tive option. If, alternatively, the patient
is not on GLP-1 RA therapy, the addition
of GLP-1 RA also shows improved glyce-
mic control and reduced insulin doses,
with the added benefit of weight loss.
Large-scale registries of real-world clin-
ical use of CSII in type 2 diabetes, pro-
viding stringent assessment of the costs,
organization, education, effect on body
weight, safety, andpotential for durability
of the glycemic control, will potentially
provide additional definition of the ideal
patient and further defineCSII positioning
with respect to new medications.
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